Correction to: npj Breast Cancer https://doi.org/10.1038/s41523-023-00579-2, published online 08 September 2023
In this article, the funding from Roche was inadvertently omitted. Additionally, in the Acknowledgements, the affiliation for Paola Tagliabue was incorrectly provided as ‘Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy’ and has been corrected to ‘Vimercate Hospital, ASST della Brianza, Vimercate, Italy’. The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Fabi, A., Carbognin, L., Botticelli, A. et al. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. npj Breast Cancer 9, 89 (2023). https://doi.org/10.1038/s41523-023-00596-1
Published:
DOI: https://doi.org/10.1038/s41523-023-00596-1
